Dublin, Dec. 9, 2014 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/mplmp3/global_lung) has announced the addition of the "Global Lung Cancer Therapeutics Market 2015-2019" report to their offering.
The use of personalized medicine is a major trend in this market. It is based on the genetic structure of the patients, and has fewer adverse side effects compared to chemotherapy, which tends to destroy other healthy cells of the body while killing the malignant cancerous cells.
According to the report, the high unmet need for appropriate drugs is one of the major factors propelling the growth of the market. Current treatment options cannot cure the disease completely; hence, the mortality rate of lung cancer patients is high. Therefore, drugs that cause disease remission in patients are expected to significantly drive the growth of the market.
Further, the report states that the high cost of treatment is a major factor that restricts the growth of the market. The drugs that are used for the treatment of cancer are expensive and, hence, get poor response from patients. The patients also tend to withdraw themselves from expensive treatment regimens.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Product Profiles
05. Market Research Methodology
07. Disease Overview
08. Market Landscape
09. Market Segmentation by Disease Type
10. Market Segmentation by Molecule Type
11. Market Segmentation by Route of Administration
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
21. Pipeline Portfolio
22. Key Vendor Analysis
23. Other Reports in this Series
- Boehringer Ingelheim
- Eli Lilly
- F. Hoffmann-La Roche
- Merck Serono
- OSI Pharmaceuticals
- Pierre Fabre
- Teva Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/mplmp3/global_lung
CONTACT: Research and Markets Laura Wood, Senior Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Lung Cancer
Source:Research and Markets